Objective More than 100 million people suffer from sleep apnea (SA) worldwide according to the WHO data. People with SA have a life expectancy 20 years shorter than the average life span. Additionally, they have a three- to sevenfold increased risk of motor vehicle crashes. The economic impact of sleep disorders is massive, specialists from the Harvard School of medicine calculated that costs of SA only in the US accounts for $115 billion every year. The main problem the world is facing with stopping the SA epidemic is not a treatment but diagnosis. It is estimated that 85% of people who suffer from SA have never been diagnosed. The reason for the low screening rate of SA is a limited access to polysomnography (PSG) – the gold standard for testing sleep disorders. At Inteliclinic, we have developed the NeuroOn-MED mask which is addressing the customers need for effective and inexpensive solution for home diagnosis of SA. Our advantage over competitors is built upon the technological excellence of NeuroOn-MED, which analyses the brainwaves and eye movements in the same way as PSG does. The sensors of NeuroOn-MED (EEG, EOG, pulse oximetry, and others) combined with artificial intelligence algorithms for sleep data analysis provide +90% of PSG effectiveness, allowing for distinguishing between sleep stages and various variants of SA. Comparing with the currently offered home sleep monitors which are capable only of diagnosing moderate and severe SA cases. Moreover, the price of our device will be lower than currently offered solutions. NeuroOn-MED is perfectly aligned with new trends in remote diagnosis of sleep disorders. The market of SA diagnostic devices is expected to reach a value of $7.3 billion in 2018, with a CAGR of 15.0%. The proposed SMEI-funded project will be focused on clinical studies of the NeuroOn-MED, which will lead to registration as a medical device and fast commercialisation on European and US markets in 2019-20. Fields of science medical and health sciencesclinical medicinepsychiatrysleep disordersnatural sciencescomputer and information sciencesdata scienceengineering and technologyelectrical engineering, electronic engineering, information engineeringelectronic engineeringsensorsnatural sciencescomputer and information sciencesartificial intelligencecomputational intelligence Programme(s) H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT) Main Programme H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument Topic(s) SMEInst-01-2016-2017 - Open Disruptive Innovation Scheme Call for proposal H2020-SMEInst-2016-2017 See other projects for this call Sub call H2020-SMEINST-2-2016-2017 Funding Scheme SME-2 - SME instrument phase 2 Coordinator INTELICLINIC SP. Z.O.O. Net EU contribution € 1 624 875,00 Address Kijowska 3 03-738 Warszawa Poland See on map Region Makroregion województwo mazowieckie Warszawski stołeczny Miasto Warszawa Activity type Private for-profit entities (excluding Higher or Secondary Education Establishments) Links Contact the organisation Opens in new window Participation in EU R&I programmes Opens in new window HORIZON collaboration network Opens in new window Other funding € 696 375,00
